Ozanimod (BioDeep_00000730834)
代谢物信息卡片
化学式: C23H24N4O3 (404.1848314)
中文名称: 奥扎莫德
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CCC(C4=CC=C3)NCCO)C#N
InChI: InChI=1S/C23H24N4O3/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3/t20-/m0/s1
描述信息
L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants > L04AA - Selective immunosuppressants
D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents > D000081243 - Sphingosine 1 Phosphate Receptor Modulators
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
C308 - Immunotherapeutic Agent > C574 - Immunosuppressant
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- KEGGdrug: D10968
- PubChem: 52938427
- DrugBank: DB12612
- ChEMBL: CHEMBL3707247
- CAS: 1306760-87-1
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Sarah Harris, Giancarlo Comi, Bruce A C Cree, Douglas L Arnold, Lawrence Steinman, James K Sheffield, Harry Southworth, Ludwig Kappos, Jeffrey A Cohen. Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.
European journal of neurology.
2021 11; 28(11):3722-3730. doi:
10.1111/ene.15009. [PMID: 34292643] - Daniel A Hussar. New Drugs 2021, Part 2.
Nursing.
2021 Oct; 51(10):18-29. doi:
10.1097/01.nurse.0000791756.56705.dd. [PMID: 34580258] - William J Sandborn, Brian G Feagan, Stephen Hanauer, Severine Vermeire, Subrata Ghosh, Wenzhong J Liu, AnnKatrin Petersen, Lorna Charles, Vivian Huang, Keith Usiskin, Douglas C Wolf, Geert D'Haens. Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study.
Journal of Crohn's & colitis.
2021 Jul; 15(7):1120-1129. doi:
10.1093/ecco-jcc/jjab012. [PMID: 33438008] - Sekhar Surapaneni, Usha Yerramilli, April Bai, Deepak Dalvie, Jennifer Brooks, Xiaomin Wang, Julie V Selkirk, Yingzhuo Grace Yan, Peijin Zhang, Richard Hargreaves, Gondi Kumar, Maria Palmisano, Jonathan Q Tran. Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator.
Drug metabolism and disposition: the biological fate of chemicals.
2021 05; 49(5):405-419. doi:
10.1124/dmd.120.000220. [PMID: 33674268] - Jerold Chun, Gavin Giovannoni, Samuel F Hunter. Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects.
Drugs.
2021 Feb; 81(2):207-231. doi:
10.1007/s40265-020-01431-8. [PMID: 33289881] - Emily Briggs, Sunny Chapel, Peijin Zhang, Maria Palmisano, Jonathan Q Tran. Concentration-QTc Modeling of Ozanimod's Major Active Metabolites in Adult Healthy Subjects.
CPT: pharmacometrics & systems pharmacology.
2021 02; 10(2):119-126. doi:
10.1002/psp4.12580. [PMID: 33314790] - Jonathan Q Tran, Peijin Zhang, Susan Walker, Atalanta Ghosh, Mary Syto, Xiaomin Wang, Sarah Harris, Maria Palmisano. Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects.
Advances in therapy.
2020 12; 37(12):4944-4958. doi:
10.1007/s12325-020-01500-0. [PMID: 33025342] - Jonathan Q Tran, Peijin Zhang, Atalanta Ghosh, Liangang Liu, Mary Syto, Xiaomin Wang, Maria Palmisano. Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study.
Advances in therapy.
2020 10; 37(10):4381-4395. doi:
10.1007/s12325-020-01473-0. [PMID: 32857315] - Silvio Danese, Federica Furfaro, Stefania Vetrano. Targeting S1P in Inflammatory Bowel Disease: New Avenues for Modulating Intestinal Leukocyte Migration.
Journal of Crohn's & colitis.
2018 Aug; 12(suppl_2):S678-S686. doi:
10.1093/ecco-jcc/jjx107. [PMID: 28961752] - Jonathan Q Tran, Jeffrey P Hartung, Cindy-Ann Tompkins, Paul A Frohna. Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator.
Clinical pharmacology in drug development.
2018 08; 7(6):634-640. doi:
10.1002/cpdd.409. [PMID: 29125718] - Kristen R Taylor Meadows, Marcos W Steinberg, Bryan Clemons, Matthew E Stokes, Gregory J Opiteck, Robert Peach, Fiona L Scott. Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus.
PloS one.
2018; 13(4):e0193236. doi:
10.1371/journal.pone.0193236. [PMID: 29608575]